News | November 04, 2025
Gland Pharma reports Q2 FY26 PAT higher at Rs. 184 Cr
Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal
Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
Building on the Merck Foundation’s longstanding commitment to advancing access to high-quality health care, new national initiative supports grants to 11 organizations across the country
PET sheets are widely recognised for their superior clarity, strength, and barrier properties
Performance driven by growth portfolio momentum, pipeline advancements, and strategic business development
Dr. Jindal reflects on bridging accessibility gaps between urban and rural regions, the ethical and emotional aspects of family building, and how initiatives like adoption facilitation centers align with his lifelong mission to help couples realize the dream of parenthood
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
Subscribe To Our Newsletter & Stay Updated
